ReviewRespiratory research2026
Single‑cell and spatial transcriptomics in chronic lung disease: cellular heterogeneity and molecular mechanisms in IPF and COPD.
Review in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) have advanced the study of complex lung diseases by resolving cellular heterogeneity, tissue architecture, and intercellular communication. These technologies are particularly informative in chronic respiratory disorders, where pathological remodeling involves coordinated alterations across epithelial, stromal, immune, and endothelial compartments. Idiopathic pulmonary fibrosis (IPF), a rare fatal fibrotic disorder, and chronic obstructive pulmonary disease (COPD), a prevalent heterogeneous respiratory condition, represent distinct chronic lung diseases shaped by persistent injury, maladaptive repair, and progressive tissue remodeling. However, current understanding of their pathogenesis remains incomplete, and conventional approaches lack the resolution to define disease-associated cell states, spatially restricted niches, or compartment-specific interactions. This review synthesizes recent scRNA-seq and ST studies in IPF and COPD, emphasizing how high-resolution atlases refine established pathobiological frameworks and reveal shared and disease-specific cellular programs. We highlight epithelial dysfunction and impaired progenitor repair as shared mechanistic features of IPF and COPD, while emphasizing alveolar regenerative failure, fibroblast activation, and profibrotic niche formation as central features of IPF, and compartment-specific airway remodeling, inflammatory epithelial states, and emphysema-associated parenchymal injury as prominent features of COPD. We further discuss stromal and immune remodeling, hypoxia-associated vascular remodeling, and the translational implications of these findings for molecular stratification, target prioritization, and mechanism-informed therapeutic development, while noting limitations related to end-stage tissue sampling, platform constraints, and mouse-human correspondence. This review provides an integrated framework for understanding the cellular and spatial mechanisms underlying the pathogenesis and translational relevance of IPF and COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.